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By using a retroviral construct derived from Moloney murine leukemia virus and capable of expressing the
dominant selectable neo gene, we measured the effects of moving or deleting a sequence (t) known to be
required in cis for the packaging of genomic RNA into virus particles. When I was at its wild-type position
(in SVX virus) near the 5' end of the RNA, the titer of infectious virus production was 5 x 106 G-418-resistant
CFU per ml. The titer was decreased approximately fivefold when W was moved, in its proper orientation, to
near the 3' end of the virus (SVX-IC) and was decreased approximately 600-fold when ' was moved, in its
proper orientation, into the U3 region of the long terminal repeat. When ' was deleted (SVX-*P) or inserted
in the opposite orientation at either of these two positions, the titer was decreased by 3000-fold relative to SVX.
In SVX-IC, W was no longer in the intron (as it is in SVX and Moloney murine leukemia virus) but was moved
to a region which is only exonic. This resulted in the encapsidation of both spliced and unspliced RNAs, their
efficient reverse transcription, and their integration into the genome of an infected cell. A number of proviruses
resulting from integration of either spliced or unspliced RNAs were cloned. Four of these clones were subjected
to sequence analysis in the region of the splice sites, and it was determined which sites are used by these viruses
and also which are used by Moloney murine leukemia virus.
For retroviruses to complete a cycle of infection, a number
of cis-acting genomic sequences are required. These include
enhancer, promoter, and polyadenylation signals which are
needed for proper mRNA synthesis and processing (1, 12,
29), primer binding sites required for reverse transcription
(7, 16, 18, 24), and signals needed for the efficient and
specific encapsidation of genomic RNA molecules into virus
particles (14, 19, 25, 26, 30).
We previously have reported the identification of a se-
quence (T) of Moloney murine leukemia virus (M-MuLV)
which, when deleted, reduced the packaging of genomic
RNA into virions to below detectability (14). Similar se-
quences have been identified in two avian viruses, spleen
necrosis virus (30) and Rous sarcoma virus (19, 25). In
M-MuLV, this sequence is located in a 350-base-pair (bp)
fragment just upstream from the initiation codon of Pr65rar.
The exact size of T is not known, but deletion analysis
demonstrates that the 3'-most 210 nucleotides of the 350-bp
fragment are not required for it to function (22; R. Mann,
unpublished data). M-MuLV genomes lacking T are defec-
tive only in cis because they can still direct the synthesis of
all viral proteins required for the assembly and budding of
infectious virus.
To extend our study of the role of I, we used a plasmid
encoding a defective derivative of M-MuLV (SVX) which is
capable of expressing the bacterial neomycin resistance gene
(neo) (2). This gene is a dominant selectable marker in
mammalian cells because it confers resistance to the com-
pound G-418 (5, 8). SVX also contains pBR322 and simian
virus 40 (SV40) sequences which allow for the efficient
rescue from cells of its proviral form.
Deletion of T from pSVX, the plasmid encoding SVX
virus, greatly reduced the titer of the virus, and replacement
of T in two new positions resulted in intermediate titers.
Movement of T away from its normal site in the intron of
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SVX to a site that is not removed during splicing resulted in
the packaging of spliced RNA molecules. This has allowed a
detailed analysis of the splice sites used by SVX and
M-MuLV to generate subgenomic mRNAs.
MATERIALS AND METHODS
Cells and viruses. NIH/3T3 fibroblasts, P2 cells (14), and
all lines derived by viral infection were grown in Dulbecco-
modified Eagle medium supplemented with 10% calf serum
at 37°C in an atmosphere of 5% CO2. Viral infections were
carried out in the presence of 8 ,ug of polybrene per ml at
37°C for 2 h. Selection for G-418-resistant clones was done
by splitting the population of infected or transfected cells at
a ratio of 1:20 into the medium described above plus 1 mg of
G-418 (GIBCO Laboratories) per ml. Individual clones were
isolated by the use of cloning cylinders and were grown in the
presence of 1 mg of G-418 per ml for at least 5 more days. A
population of G-418-resistant clones was obtained by growth
in mass culture of all clones which grew in one or more of the
selection dishes.
Cloned DNAs. Plasmid pSVX has been described by
Cepko et al. (2). pSVX-T- was constructed by using BamHI
linkers to change the HindIll site (at 0.7 units) of pMOV-4I-
(14) to a BamHI site. A long terminal repeat (LTR)-
containing the XbaI to BamHI fragment was isolated by
preparative low melt agarose gel electrophoresis and in-
serted into pSVX in place of the approximately 0.7-kilobase-
pair (kb) XbaI to BamHI fragment, thus incorporating the
P- deletion into the SVX virus. pSVX-PC (proper orienta-
tion of T) and pSVX-TC (opposite orientation of T) were
constructed by ligating a blunted, ClaI-linkered BalI (0.7
units) to PstI (1.0 units) fragment of pMOV-9 (4) into the
unique ClaI site ofpSVX-P-. pSVX-PX (proper orientation
of P) and pSVX-PX (opposite orientation of I) were
constructed by ligating this same fragment, linked with
XbaI, into the XbaI site in the 3' LTR of pSVX-P-. All
linkers were obtained from Collaborative Research, Inc.
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Derivation of cell lines. The cell line SVX/T2-9, which
produces SVX virus, was generated by transfectingT2 cells
with pSVX, selecting for G-418 resistance, and picking
independent colonies. SVX/T2-9 produced the highest titer
among 15 such clones. The cell lineTC/T2-9, which produces
SVX-TC virus, was generated by transfectingT2 cells with
pSVX-TC, selecting for G-418 resistance and picking inde-
pendent colonies.TC/T2-9 produced the highest titer among
15 such clones. T-/T2-1 and T-/T2-2, which produce
SVX-T- virus, were generated by transfectingT2 cells with
pSVX-T-, selecting for G-418 resistance and picking inde-
pendent colonies. The cell lines SVX-1 and SVX-2 were
derived by infecting NIH/3T3 cells with supernatants from
T2 cells that had been transfected with pSVX 20 h earlier
(transiently derived virus). The cell lines TC-1, TC-2, and
PC-3 were derived by infecting NIH/3T3 cells with super-
natants fromT2 cells that had been transfected with pSVX-
TC 20 h earlier (transiently derived virus). The cell lines
TC9-3 and TC9-6 were derived by infecting NIH/3T3 cells
with virus obtained from the PC/P2-9 cell line. In all of the
infections described above, the NIH/3T3 cells were selected
for G-418 resistance, and independent colonies were picked.
Analysis of cellular DNA. High-molecular-weight DNA
was isolated from tissue culture cells as described previously
(13), and portions were digested with the appropriate restric-
tion endonucleases and ethanol precipitated. The DNA
fragments were separated in a horizontal agarose gel in
Tris-borate buffer as described previously (13) and trans-
ferred to nitrocellulose filters (Schleicher & Schuell, Inc.) as
described previously (13). The immobilized DNA was hy-
bridized to pSV2neo (27) plasmid that was 32P-labeled by
nick-translation (13). The hybridization and wash conditions
were as described previously (13).
Mammalian cell transfections and transformations. The
method of mammalian cell transfection and transformation
employed here was identical to that used by Mann et al. (14).
Preparation of RNA. Total cellular RNA was prepared as
described previously (3). Virion RNA was prepared by
phenol extraction of virions banded in a sucrose step gradi-
ent (24).
Si nuclease analysis. Twenty micrograms of total RNA
was hybridized in 20 >d of hybridization buffer (10) with a
DNA fragment labeled at the 5' end with 32p. The hybridi-
zation was at 48°C for 12 to 16 h. The hybrids were digested
with 50 units of Si nuclease (P-L Biochemicals, Inc.) at 37°C
for 1 h in 400 pl of Si buffer. The protected DNA fragments
were separated by electrophoresis through 6% polyacryla-
mide-urea gels which were exposed to X-ray film (Kodak
XAR5) with an intensifying screen (Du Pont Lightning Plus)
at -70°C. The fragment labeled at the 5' end with 32p was
prepared by digestion of pSVX with XhoI followed by
removal of the 5'-terminal phosphate with calf intestinal
phosphatase (Boehringer Mannheim Corp.). The DNA was
labeled with T4 polynucleotide kinase (Bethesda Research
Laboratories) and [-y-32P]ATP (ICN Pharmaceuticals, Inc.)
and was then digested with XbaI. The T-containing,
end-labeled fragment was isolated by electrophoresis on a
1% low melt agarose gel.
Cloning of integrated proviruses. The method for cloning
SVX proviruses was as described by Cepko et al. (2).
Briefly, the cell line harboring the provirus to be cloned was
co-plated with SV40 T-antigen containing COS cells. The
plate was grown to confluence, and the cells were fused with
polyethylene glycol. After 2 days of incubation, low-molec-
ular-weight DNA was isolated by the removal of the Hirt
precipitate with a centrifuge. The supernatant was phenol
extracted and ethanol precipitated. A portion of the redis-
solved material was used to transfect Escherichia coli HB101
followed by selection for kanamycin resistance. In general,
plasmid from six kanamycin-resistant colonies was isolated
for each proviral cloning to ensure that the plasmid structure
accurately represented the proviral structure.
DNA sequence analysis. Plasmids whose splice site regions
were to be sequenced were digested with AvaIl and the
fragment containing the splice sites was isolated by prepar-
ative low melt agarose gel electrophoresis. The AvaIl frag-
ments were end labeled as described above for the prepara-
tion of the Si nuclease probe. The labeled fragments were
strand separated as described previously (13), and both
strands were subjected to sequencing reactions by the method
of Maxam and Gilbert (15). The products were electrophor-
esed through 8% polyacrylamide urea gels, which were then
exposed to X-ray film with an intensifying screen at -70°C.
RESULTS
To determine whether the sequence required in cis for
encapsidation of genomic RNA into virus particles (P) can
function at more than one location, we varied its position
along the RNA and studied these variants in a series of
transfection experiments. The proviral structures of these
variants are illustrated in Fig. 1. The parent plasmid pSVX
had its packaging site in the wild-type position (2). This
position is between the 5' and 3' splice sites of this virus and,
therefore, will be considered part of an intron. This intron is
unusual because it is removed from only about one-half of
the transcripts (see below). pSVX and its derivatives are
capable of expressing the dominant selectable marker (neo)
which confers resistance to kanamycin in bacteria and to the
drug G-418 in mammalian cells (5, 8). The first variant,
pSVX-T-, had a deletion of the 350-bp fragment previously
identified to contain a cis packaging sequence (14). pSVX-
TC had the same deletion as pSVX-T- but also had the
350-bp fragment translocated in its proper orientation to the
ClaI site near the 3' end of the provirus. pSVX-PX had the
350-bp fragment translocated to the XbaI site in the 3' LTR.
Each of these plasmids was transfected into the T2 packag-
ing cell line (14), and virus production was measured by two
assays. The transient assay consisted of determination of the
titer of G-418-resistant CFU per milliliter (G-418r CFU/ml)
by infection of NIH/3T3 cells with culture supernatants
obtained 20 h posttransfection. The stable assay involved
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FIG. 1. Structure of the proviral forms of SVX and its deriva-
tives. SVX has P in the wild-type position, SVX-P- has T deleted,
SVX-PC has AI inserted in the proper orientation at the Clal site,
and SVX-PX has 'I inserted in the proper orientation at the XbaI
site. Abbreviations: C, ClaI; X, XbaI; ss, splice site; the LTRs, neo
gene, and pBR322 (pBR) plus SV40 origins of replication are
indicated.
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determination of the titer of G-418r CFU/ml by infection of
NIH/3T3 cells with culture supernatants from a population
of stable G-418r T2 transfectants. Each population consisted
of 100 to 200 independent G-418r events to minimize differ-
ences due to the position or copy number of the transfected
DNA. All plasmids were capable of generating G-418r virus
to grossly varying degrees (Table 1). With pSVX as the
standard, pSVX-TC was approximately four- to sixfold less
efficient, pSVX-PX was about 600-fold less efficient, and
pSVX-T- was about 3000-fold less efficient at producing
G-418r CFU when transfected into T2 cells. Plasmids in
which the packaging site was inserted in the opposite onen-
tation at the ClaI (pSVX-TC) or the XbaI (pSVX-IX) sites
yielded titers equivalent to those of pSVX-T-.
The proviral structure of G-418-resistant NIH/3T3 clones
infected with transiently obtained SVX or SVX-TC virus
was analyzed by restriction enzyme cleavage and hybridiza-
tion with 32P-labeled neo sequences (Fig. 2). Two indepen-
dently obtained SVX-infected cell lines (SVX-1 and SVX-2)
yielded the expected fragments on digestion with BamHI
plus XbaI (3.5-kb; lanes 1 and 2, Fig. 2) and with EcoRI plus
XbaI (2.8-kb; lanes 6 and 7, Fig. 2). Two patterns were
obtained among three independent SVX-TC-infected cell
lines. TC-1 had the expected structure, generating a 3.8-kb
band on BamHI plus XbaI digestion (lane 3, Fig. 2) and a
2.5-kb band on EcoRI plus XbaI digestion (lane 8, Fig. 2).
TC-2 and TC-3 had different structures: a 4.0-kb band on
BamHI plus XbaI digestion (lanes 4 and 5, Fig. 2) and a
2.4-kb band on EcoRI plus XbaI digestion (lanes 9 and 10,
Fig. 2). This novel pattern could be explained by a small
deletion within the provirus which removed the BamHI site.
Thus, the BamHI plus XbaI digest would result in a 4.0-kb
XbaI to XbaI hybridizable fragment, and the EcoRI plus
XbaI digest would yield a 2.4-kb fragment because of a
deletion of approximately 100 bp.
A splice between M-MuLV 5' and 3' splice sites in
SVX-TC could account for the small deletion that removed
the BamHI site and resulted in the proviral structure found
in the TC-2 and TC-3 cell lines (Fig. 2). Such an interpre-
tation implies that spliced SVX-TC RNA can be packaged
into virus particles, can be efficiently reverse transcribed,
and can be integrated into the genome of an infected cell. To
directly test whether spliced RNAs were encapsidated in a
stable SVX-TC producer cell line (PC/P2-9), an Si nuclease
analysis was used (Fig. 3). Cellular RNA from a cell line
producing standard SVX virus (SVX/T2-9) protected a
950-bp fragment corresponding to unspliced RNA (band I,
Fig. 3) and a 280-bp fragment corresponding to spliced RNA
(band III, lane 1, Fig. 3). The intensities of these two bands
ranged, among a number of experiments, from a ratio of 1:1
to 1:5 of unspliced:spliced RNA. This demonstrates that, as
in M-MuLV, a significant amount of retroviral RNA, at
TABLE 1. Production of virus (G-418r CFU) by pSVX and its
derivatives
Titer of virus produced (CFU/ml)
Plasmid
Transient Stable
pSVX 850 4.0 x 106
pSVX-T- <10" 1.2 x 103
pSVX-TC 150 1.0 X 106
pSVX-PX <10" 7.0 x 103
pSVX-TC <10" 1.2 x 103
pSVX-PX <10" 1.1 X 103
" No G-148r CFU were observed.
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FIG. 2. Hybridization analysis of G-418r cell lines infected with
SVX or SVX-'IC virus. SVX-1 and SVX-2 were derived by infec-
tion of NIH/3T3 cells with transiently obtained SVX virus. P-1,
4f-2, and T-3 were derived by infection of NIH/3T3 cells with
transiently obtained SVX-TC virus. Abbreviations: Bam, BamHI;
RI, EcoRI; Xba, XbaI; Cla, ClaI; ss, splice site. The structures of
SVX and SVX-PC are shown with the relevant restriction endonu-
clease sites. Numbers to the right and left of the gel are in kb.
steady state, remains unspliced. SVX virion RNA protected
only a 950-bp fragment of probe DNA (lane 2, Fig. 3). Other
faint bands seen in these two lanes were probably due to
protection by specific degradation products of the unspliced
RNA.
Cellular RNA from a cell line producing SVX-TC virions
(TC/T2-9) protected a 380-bp fragment corresponding to
unspliced RNA (band II, Fig. 3) and a group of three bands
(band III, Fig. 3), ranging from about 295 to 270 bp, which,
as will be shown below, correspond to different spliced RNA
species (lane 3, Fig. 3). SVX-TC virion RNA protected both
unspliced (band II, Fig. 3) and spliced (band III, Fig. 3)
RNAs (lane 4, Fig. 3). Therefore translocation of the 350-bp
P fragment from the intron of the virus to the exon se-
quences at ClaI resulted in the encapsidation of both spliced
and unspliced RNAs in contrast to virus with T in intron
sequence which packaged only unspliced RNA.
The proviral form of the SVX virus family can be easily
cloned in E. coli (see Cepko et al. [2] for a detailed
description). This was done for a number of G-418r NIH
3T3-infected cell lines harboring SVX, SVX-P- or SVX-TC
proviruses (Table 2). By restriction endonuclease analysis
four of four cloned SVX proviruses had a structure identical
to that of the original SVX construction; i.e., no rearrange-
ments were observed. Cloned SVX-TC proviruses were of
two general structures: either identical to the original SVX-
TC construction (three of nine) or equivalent to a cDNA
copy of spliced SVX-TC RNA (six of nine). The structure of
VOL. 54, 1985 403
404 MANN AND BALTIMORE
SVX/*2-9 C/42-9
M C V cC V i-
-I
527- _
404- _
_
-E
309- _
242-_
2 3 4 5
X ba CAP 5'ss , 3'ss Xhos.lI A I1--AS' I
9IOOb "PROBE
'I
Xba CAP 51, Xho
= b':LT SV X-*C
350 bp
__4
FIG. 3. Si nuclease analysis of cellular and viral RNAs from a
SVX producer line (SVX/P2-9) and a SVX-PC producer line (TC/
T2-9). Abbreviations: M, marker; C, cellular RNA; V, virion RNA;
ss, splice site. L cell RNA (lane 5) was used as a negative control.
Band I corresponds to full-length SVX RNA, band II corresponds to
full-length SVX-PC RNA, and band III corresponds to spliced RNA
from both SVX and SVX-PC. The structure of the relevant regions
of the two viruses are shown with the S1 nuclease probe and
expected sizes of the various protected fragments. CAP is the site of
initiation for RNA synthesis. Numbers to the left of the gel are the
sizes of the marker bands in bases.
3' splice sites (Fig. 4). The provirus in AYC9-6, which was
derived by infection with NVC/IP2-9 virus, used a 3' splice site
designated B, whereas the provirus in TC-2, which was
derived by infection with transiently obtained virus, used a
3' splice site designated A. The choice of 3' splice site A, but
not B, created a SacI restriction endonuclease recognition
sequence (Fig. 4). Thus, all other cloned proviruses that
were derived from spliced RNA could be screened to
determine which 3' splice site was used by screening for the
presence of the Sacl site. The presence of the Sacl site was
taken as strong evidence that 3' splice site A had been used.
Only proviruses generated by virus obtained from the 'C/
T2-9 cell line lacked the Sacl recognition sequence at the
splice joint, suggesting that the use of 3' splice site B is
peculiar to that cell line (Table 2).
The Si nuclease pattern of the TC/T2-9 cell line was
peculiar in that three protected fragments were generated
which all mapped close to the 3' splice site (band III, Fig. 3).
Because spliced proviruses generated from TC/T2-9 virus
used 3' splice site B, it seemed likely that the largest and
most abundant band in this triplet would correspond to this
splice site. Similarly, the next smaller band, which appears
identical in size to the band present in lane 1 (Fig. 3) (the 3'
splice site used in SVX), would correspond to 3' splice site
A. This was demonstrated by Si nuclease analysis of cellular
RNAs from the various G-418r-infected cell lines harboring
those SVX-TC proviruses which had been cloned and
sequenced (Fig. 5). Lanes 1 and 2 in Fig. 5 repeat the Si
protection patterns of the SVX/T2-9 and TC/T2-9 producer
cell lines that were seen previously (Fig. 3, lanes 1 and 3).
Cell line PC9-6, which by sequence analysis had a provirus
generated from an RNA spliced to 3' splice site B, generated
the largest of the triplet of protected bands on Si analysis
(lane 4, Fig. 5). Cell line TC-2, which by sequence analysis
had a provirus generated from a spliced RNA that used 3'
splice site A, generated the middle band of the triplet on Si
analysis (lane 6, Fig. 5). This band is identical to that
protected by RNA from SVX/T2-9 (lane 1, Fig. 5). The 3'
splice site A was also used in cell lines 'C-1 (lane 3, Fig. 5)
and TC9-3 (lane 5, Fig. 5). These cell lines also contained
full-length SVX-TC RNA (i.e., protected the 380-bp frag-
ment) because they harbored an unspliced provirus. Among
all the cell lines infected with PC/42-9 virus, none harbored
a provirus which corresponded to an RNA capable of
protecting the smallest of the fragments present in lane 2
(Fig. 5). This is probably due to the low abundance of this
RNA relative to the other SVX-TC RNAs in the IPC/T2-9
cell line.
cloned SVX-T- proviruses were also either identical to the
input plasmid (four of seven) or equivalent to a cDNA of
spliced SVX-T- RNA (three of seven) (Table 2). In all seven
cases examined, proviruses derived from SVX-P- virus did
not contain a T sequence, as determined by restriction
mapping of the cloned proviruses.
Four of the cloned SVX-TC proviruses were sequenced in
the region around the splice sites (Fig. 4). Two unspliced
proviruses (one from TC-1, infected with transiently derived
virus, and one from TC9-3, infected with TC/T2-9 virus)
had identical sequences in the Avall fragment containing the
splice sites. Sequences of two spliced SVX-TC proviruses
differed by 14 nucleotides because of the use of two different
TABLE 2. Cloned proviruses
No. of proviruses with
DNA Source of Titer the following structure
virus (CFU/ml)' Spliced
Unspliced(A or B)"
PSVX Transient 1 X 103 1 0
SVX/I2-9 5 x 106 3 0
PSVX-p- Transient < 10' 0 0
fI-/T2-1 1 X 103 2 1 (A)
V-/N2-1 4 x 102 2 2 (A)
pSVX-PC Transient 2 x 102 1 2 (A)
'IC/I'2-9 1 X 106 2 4 (B)
"Titer is G-418' CFU/ml of culture supernatant.
bA or B refers to which 3' splice site was used.
' No G-418' CFU were observed.
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Avail 20 5'ss 40 BamHI 60 80
4IC-1,*lC9-3 HACCGACCCACCACCGG(3CGGTAA(dTGGCCAAGCTCGGCCAAGCTCGGATCCGGGATCTTATATGGGGCACCCCCGC
4iC9-6 ACCACCGACCCACCACCGGGAG
* C-2 ACCACCGACCCACCACCGGGAG
SacI
*kC-1,jC9-3
*C9-6
*rC-2
*0C-1 *C9-3
*C9-6
*C-2
100 3'ss B 3'ss A 160
CCCTTGTAACTTCCCTGACCCTGACATCACAAGAGlTAT CCC iKTCTCCAAdTCACTTACAGGCTCTCTAC
CCCCTCTCTCCAAGCTCACTTACAGGCTCTCTAC
CTCACTTACAGGCTCTCTAC
Sacl
180 2° AvaU
TTAGTCCAGCACGAAGTCTGGAGACCTCTGGCGGCAGCCTACCAAGAACAACTGGA
TTAGTCCAGCACGAAGTCTGGAGACCTCTGGCGGCAGCCTACCAAGAACAACTGGA
TTAGTCCAGCACGAAGTCTGGAGACCTCTGGCGGCAGCCTACCAAGAACAACTGGA
FIG. 4. Sequence comparison of the splice site region from four SVX-TC proviruses. Consensus sequences (as compiled in references 23
and 17) for the 5' splice site and two 3' splice sites (A and B; see text) are boxed. A solid line represents the absence of nucleotides. TC-1
(unspliced) and 'IC-2 (spliced) are derived from transiently derived virus. PC9-3 (unspliced) and TC9-6 (spliced) are derived from virus
obtained from the producer line PC/P2-9. The Avall (where sequencing began), Sacl (present only in TC-2), and BamHI restriction
endonuclease sites are shown.
DISCUSSION
Having previously shown that a 350-bp fragment (T) of
M-MuLV is required in cis for encapsidation of genomic
RNA into virions (14), we show here that this fragment can
function in a variety of positions within the viral genome.
When T is at the ClaI site in pSVX-TC, the virus titer was
only fivefold lower than when T was in its wild-type
position. SVX-PX virus had a much lower titer than wild-
type SVX virus but clearly above that of SVX-T-, the virus
from which the entire 350-bp fragment had been deleted. The
relatively poor transmission efficiency of SVX-PX virus
may or may not be due to an encapsidation problem because
deleterious effects on other steps in the retroviral life cycle
would also adversely affect the G-418r CFU titer. One
potential problem in SVX-PX is that the inserted T se-
quence separates the viral enhancer (12) from the promoter
elements which may result in a reduction in the transcription
of the neo gene.
The ability to translocate T from near the 5' end of viral
RNA to near the 3' end demonstrates that the T function is
relatively autonomous of neighboring sequences. The func-
tion of T is not, however, completely independent of posi-
tion. A fivefold lower titer was produced when T was at the
ClaI site, which may either be a consequence of partial
occlusion by the surrounding sequence or an indication that
T acts more efficiently when it can interact with the correct
neighboring sequences.
Although producer cell lines harboring the pSVX-T-
plasmid yield G-418r CFU 3000-fold less efficiently than cell
lines containing wild-type pSVX, it was surprising that the
SVX-T- titers were as high as 103 CFU/ml (Table 1). This
titer is a measure of the leakiness of the 350-bp P- deletion
mutation because these genomes are packaged without a P
sequence. This number may also reflect the leakiness of
packaging mutations incorporated into replication compe-
tent retroviruses (6, 14, 26) and should be considered when
these systems are to be used to generate "helper-free"
retroviral stocks. If T- helper genomes are packaged with a
similar efficiency to SVX-T- RNA, then these RNAs could
be substrates for recombination with T' RNAs to generate
fully competent helper virus. The T2 cell line, which is such
a system for producing helper-free stocks, has not been
observed to yield wild-type M-MuLV even with high titer
infections (R. Mann and R. Mulligan; unpublished data).
This apparent inconsistency suggests that the M-MuLV
genome present in T2 may harbor a mutation in addition to
the 350-bp P deletion which reduces the propensity of the
helper genome to generate wild-type virus to below detect-
ability. The second mutation need not affect packaging; it
could also prevent reverse transcription or integration. (In
our previous study [14] we reported that transfection of
pMOV-T- [an M-MuLV proviral clone with T deleted] into
NIH/3T3 cells eventually resulted in the production of
wild-type virus, although at a much slower rate than trans-
fection of the wild-type clone pMOV-AP. With other prep-
arations of pMOV-P- plasmid, however, production of
wild-type virus has not been observed, suggesting that the
original plasmid preparation may have had a small amount of
contaminating pMOV-TP plasmid.)
The 103 G-418r CFU SVX-T- titer may imply that there
are other signals on retroviral genomic RNA that are impor-
tant for packaging. The avian retrovirus, Rous sarcoma
virus, appears to have at least two sites that are each
necessary for encapsidation. One site is located within the
gag coding sequence, about 140 nucleotides downstream
from the 5' splice site (19). A second site resides within a
115-nucleotide sequence which is present both upstream and
downstream of the v-src gene (25). These sites may act
coordinately in providing genomic RNA with the proper
specificity required for efficient packaging.
By moving the 350-bp T fragment from the intron of
pSVX to a site where it is not removed by splicing (in
pSVX-TC), spliced and unspliced RNAs could be efficiently
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FIG. 5. S1 nuclease analysis of cellular RNAs from producer and
infected cell lines. Lanes 1 and 2, RNAs from SVX/T2-9 (producer
of SVX virus) and TC/T2-9 (producer of SVX-PC virus), respec-
tively; lanes 3 and 6, RNAs from WC-1 and PC-2, respectively
(generated by infection with transiently derived SVX-PC virus);
lanes 4 and 5, RNAs from TC9-6 and 'IC9-3, respectively (gener-
ated by infection with SVX-PC virus from the TC/qI2-9 producer
cell line). The S1 probe is identical to that used in Fig. 3. M, Marker.
Numbers to the left of the gel are the sizes of the marker bands in
bases.
encapsidated, reverse transcribed, and integrated into the
genome of an infected cell. We have used this fact, coupled
with the ease of cloning proviruses of SVX and its deriva-
tives, to analyze in detail the splice sites which these viruses
use. The splice sites present in pSVX are identical to those
in M-MuLV, except for an approximately 5-kb deletion of
intronic sequence (from PstI [1.0 unit] to BglII [5.9 units]),
leaving an intron of about 460 nucleotides. The intron
present in pSVX-P- and pSVX-TC is further reduced to
about 110 nucleotides because of the deletion of the
fragment. The splicing reaction for all three of these con-
structs yields approximately 30% unspliced and 70% spliced
RNA (Fig. 2, Table 2) as does the splicing reaction in the
wild-type situation of M-MuLV (9, 21). Therefore, deletion
of98% of the intron does not measurably affect the efficiency
of splicing. These results support previous studies on the
,B-globin gene which indicate that no specific internal intron
sequence is required for accurate splicing (20, 31). In con-
trast, however, Hwang et al. (11) have reported recently the
existence of two regions of the M-MuLV intron which, when
either is deleted, adversely affect splicing. These regions are
absent from all of the SVX viruses studied here without
affecting splicing. The inefficient splicing described by Hwang
et al., therefore, is likely due to some peculiarity of their
constructions, such as the particular secondary structure of
the RNAs transcribed from them, and probably is not due to
the absence of a sequence essential for splicing.
Two 3' splice sites, separated by only 14 nucleotides, were
observed in these studies. The more predominant one (3'
splice site A) is used by SVX (lane 1, Fig. 5), SVX-T- and
SVX-TC (Table 2) and therefore is probably the site used by
M-MuLV. The only situation in which 3' splice site B was
used was in the producer line TC/T2-9 or in lines derived
from TC/T2-9 virus (Fig. 5, Table 2). This suggests that at
least one of the copies of the pSVX-TC construct introduced
by transfection into this line harbored a mutation which
activated this normally cryptic splice site. Activation of
cryptic splice sites has been observed in a variety of genes
and can result from mutations at the normal splice site or at
the newly activated splice site (28, 32). The TC/T2-9 cell
line must also contain at least one copy of an unmutated
SVX-TC genome because the cell line TC9-3, which was
infected by TC/T2-9 virus, contained an unspliced provirus
which used only 3' splice site A (Fig. 5). The TC/T2-9 cell
line, therefore, probably expresses two types of SVX-TC
genomes: one which produces large amounts ofRNA spliced
to 3' splice site B (as in lane 4, Fig. 5) and one which splices
to 3' splice site A (as in lane 5, Fig. 5).
The smallest fragment protected by TC/T2-9 RNA (lane
2, Fig. 5), may correspond to another spliced RNA that has
chosen a second cryptic 3' splice site. Because no provirus
corresponding to this RNA was observed, it cannot be
determined whether this RNA is, in fact, a third spliced
species. It is peculiar that this same fragment is protected by
TC9-6 RNA (lane 4, Fig. 5). In this cell line, the provirus is
derived from an RNA spliced to 3' splice site B. Therefore,
the usual 5' splice site should no longer be available to
generate any other spliced RNAs.
Although the packaging sequence is able to function at
sites other than its wild-type position, there may be other
reasons which make some positions more favorable than
others. When T is at ClaI (in SVX-TC), RNA is efficiently
packaged, but no distinction is made between the packaging
of unspliced and spliced RNAs because both species contain
the 350-bp T fragment. In M-MuLV, with T at its wild-type
position, the packaging signal is removed during the produc-
tion of the spliced env mRNA, preventing the env gene from
being transmitted by itself to an infected cell. Transmission
of an env-only retroviral RNA would be detrimental to the
spread of M-MuLV because expression of the env protein
alone could block any further infection by M-MuLV.
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